2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 1/2
1
Status
Completed
3
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
3
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Carcinoma
1
Adenoviridae Infections
1
Interventions
Oxaliplatin
1439
Fluorouracil
1319
Capecitabine
1114
Gemcitabine
1057
Leucovorin
939
Bevacizumab
847
Irinotecan
830
Cisplatin
676
Radiotherapy
560
Cetuximab
482
pembrolizumab
435
Paclitaxel
401
Drug Therapy
358
Nivolumab
350
130-nm albumin-bound paclitaxel
329
Docetaxel
290
Sorafenib
288
S 1 (combination)
279
Folfox protocol
266
Albumin-Bound Paclitaxel
263
Surgical Procedures, Operative
258
lenvatinib
222
sintilimab
218
tislelizumab
214
durvalumab
212
regorafenib
209
Magnetic Resonance Spectroscopy
205
apatinib
204
Radiosurgery
204
Neoadjuvant Therapy
190
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
enadenotucirev
×
Gastrointestinal
×
Clear all
NCT03916510
2025-02-06
CEDAR
University of Oxford
Phase 1
Completed
12 enrolled
13 charts
NCT02636036
2021-11-09
SPICE
Akamis Bio
Phase 1
Completed
51 enrolled
NCT02028442
2020-03-12
EVOLVE
Akamis Bio
Phase 1/2
Completed
61 enrolled